AbbVie (NY:ABBV)

These stocks are keepers.

Topics Economy

3 Stocks I Plan to Hold for the Next 20 Years ↗

April 18, 2026

Founders of the Integrative Psychiatry Institute, Dr. Will Van Derveer and Keith Kurlander, discuss their new book, Psychedelic Therapy: A Revolutionary Approach to Restoring Mental Health and...

Topics Artificial Intelligence Intellectual Property

The Psychedelic Revolution in Mental Healthcare ↗

April 17, 2026

The pharma giant is still a rock-solid dividend stock.

Why AbbVie Is a No-Brainer Stock to Buy on the Dip ↗

April 16, 2026

Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The ...

1 Value Stock Worth Your Attention and 2 That Underwhelm

April 16, 2026

These stocks pay between 3.3% and 6.3% and are backed by strong financials.

3 High-Yielding Dividend Stocks to Buy, Even If You're Worried About the Market ↗

April 15, 2026

AbbVie is making progress in this market, but it is still far behind the leader.

Could AbbVie Crash Lilly's Weight‑Loss Party? ↗

April 14, 2026

The RAS Revolution: A Deep Dive into Revolution Medicines’ Path to Dominance (2026 Report)

April 14, 2026

As of today, April 14, 2026, the biotechnology landscape is being reshaped by a singular clinical milestone that many once deemed impossible. Just twenty-four hours ago, Revolution Medicines, Inc....

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

This Indicator Has Called Every Recession Over the Last 80 Years. Here's What It's Saying Now. ↗

April 14, 2026

The U.S. economy could be starting a vicious cycle if this indicator is right.

The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...

Topics Economy

2 S&P 500 Stocks with Solid Fundamentals and 1 We Brush Off

April 14, 2026

As of today, April 13, 2026, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stands as a titan of the biotechnology sector, representing a rare blend of scientific purity and commercial dominance. In an...

Topics Stocks

The Science of Scale: An In-Depth Look at Regeneron Pharmaceuticals (REGN) in 2026

April 13, 2026

Via Finterra

Topics Earnings Economy Intellectual Property

S&P 500 Index Dividend Yields Are Teasing All-Time Lows. Here Are 3 Dividend Darlings That Crush This Trend. ↗

April 13, 2026

There are still some generous yielders if you know where to look.

Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ...

Topics Stocks

3 Market-Beating Stocks with Competitive Advantages

April 10, 2026

Gilead Sciences Solidifies Oncology Future with $5 Billion Acquisition of ADC Innovator Tubulis

April 09, 2026

In a bold move to dominate the rapidly evolving cancer treatment landscape, Gilead Sciences (Nasdaq: GILD) announced on April 7, 2026, its acquisition of the German biotech firm Tubulis for a total...

The calendar says it’s spring, but investors can’t be blamed for feeling like it’s Groundhog Day: The economic issues impacting portfolios continue to persist this year. Just after a ceasefire between...

Topics Bonds

3 Dividend Aristocrats Whose Yields Can Help Combat Inflation ↗

April 09, 2026

Via MarketBeat

Topics Economy

3 Companies Aggressively Raising Dividends While Others Play Defense ↗

April 09, 2026

A strong dividend stock may not only pay a healthy distribution, but also be able to continue to grow its payouts thanks to steady, strong business.

Via MarketBeat

Topics Artificial Intelligence Economy

This Investor's $5 Million ETF Buy Pushes 2028 Bond Fund to Nearly 4% of AUM ↗

April 09, 2026

The Invesco BulletShares 2028 Corporate Bond ETF holds a diversified portfolio of investment-grade U.S. corporate bonds maturing in 2028.

This ETF targets investment-grade U.S. corporate bonds maturing in 2027, offering defined duration and a predictable income stream.

Topics Bonds ETFs Regulatory Compliance

This Fund's Ladder Strategy Expanded With a $4 Million Buy in One 2027 Bond ETF ↗

April 09, 2026

Red Spruce Adds $3.35 Million to a 2029 Bond ETF With 4.5% Yield. Here's What Investors Should Know ↗

Topics Bonds ETFs

April 09, 2026

The Invesco BulletShares 2029 Corporate Bond ETF targets investment-grade U.S. bonds maturing in 2029 with a defined maturity structure.

From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on...

Topics Bonds ETFs Regulatory Compliance

1 Healthcare Stock on Our Watchlist and 2 We Avoid

April 09, 2026

These stocks offer high yields and trade at incredibly low earnings multiples.

3 Absurdly Cheap Dividend Stocks to Buy in April 2026 ↗

April 08, 2026

Spun off from a Dividend King in 2013, this pharmaceutical stock is a rising star among dividend growth stocks.

Topics Economy

This Pharma Dividend Has Been Raised Every Single Year for Over a Decade ↗

April 07, 2026

The healthcare giant reports earnings in three weeks.

Topics Intellectual Property

Should You Buy AbbVie Stock Before April 29? ↗

April 07, 2026

The "Liberation Day" Shockwave: US Finalizes 100% Tariffs on Branded Pharmaceutical Imports

Topics Intellectual Property

April 06, 2026

In a move that has sent shockwaves through the global healthcare industry, the U.S. Administration officially finalized a sweeping new trade policy on April 6, 2026, imposing 100% tariffs on branded...

Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation

Topics Economy World Trade

April 03, 2026

By Financial Research Feature April 3, 2026 Introduction In the high-stakes arena of global biotechnology, Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has long stood as a paragon of scientific...

Via Finterra

Topics Economy Intellectual Property World Trade

2 Healthcare Dividend Stocks to Buy as the Tech-Heavy Nasdaq Dips Below Correction Territory ↗

April 02, 2026

Dividend payers might become more popular if the recent volatility continues. These two stocks are great picks to weather the storm.

Merck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer

Topics Economy Retirement Stocks

April 02, 2026

BRUSSELS — In a major victory for one of the world’s leading pharmaceutical giants, the European Commission (EC) has officially granted marketing authorization for Merck & Co. (NYSE: MRK) blockbuster...

AMN Healthcare Services, DaVita, Bristol-Myers Squibb, Novavax, and AbbVie Shares Plummet, What You Need To Know

Topics Intellectual Property

April 02, 2026

What Happened? A number of stocks fell in the afternoon session after reports revealed that the US may impose up to 100% tariffs on imports of branded and pa...

As we enter the second quarter of 2026, Johnson & Johnson (NYSE: JNJ) stands as a starkly different entity than the consumer-facing conglomerate that defined the 20th century. Having successfully shed...

Topics Government Stocks World Trade

The New Blue-Chip: How Johnson & Johnson Refined Its Empire for a High-Growth Future

April 01, 2026

Via Finterra

Topics Artificial Intelligence Earnings Economy

Gilead Sciences Acquires Ouro Medicines for $2.2 Billion to Lead 'Immune Reset' Revolution

March 31, 2026

In a move that signals a decisive shift in the treatment of chronic autoimmune conditions, Gilead Sciences (NASDAQ:GILD) announced on March 23, 2026, its definitive agreement to acquire Ouro Medicines...